3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
pembrolizumab
25
Cisplatin
20
Carboplatin
14
Paclitaxel
11
Radiotherapy
9
Radiotherapy, Intensity-Modulated
8
Docetaxel
8
Cetuximab
8
Nivolumab
7
cemiplimab
5
Radiation
5
durvalumab
4
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Fluorouracil
3
Drug Therapy
3
Cyclophosphamide
3
Blood Specimen Collection
3
toripalimab
2
olaparib
2
fludarabine
2
avelumab
2
alpha-2'-deoxythioguanosine
2
aldesleukin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
vistusertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
Nimorazole
×
1 year
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled